Patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer received IMGN853 at 6.0 mg/kg (adjusted ideal body weight) once every 3 weeks. Eligibility included a ...

(RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has granted full approval for Elahere (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha-positive, ...

The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to mirvetuximab soravtansine-gynx for treatment of certain adults with ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and ...

The European Medicines Agency's (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorization of mirvetuximab soravtansine (Elahere; AbbVie) for folate ...

Sarasota Memorial Hospital is conducting a clinical trial for a new ovarian cancer drug, Mirvetuximab Soravtansine. The drug targets the protein folate receptor-alpha, often found in high levels in ...

The US Food and Drug Administration granted full approval to mirvetuximab soravtansine-gynx (Elahere) for adults with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian ...

The confirmatory trial showed limited side effects relative to physician's choice of chemotherapy. For certain women with recurrent ovarian cancer, results presented early today at the American ...

NORTH CHICAGO, Ill., Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., ...